Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.CMC Biologics has entered a three-year agreement with Daiichi Sankyo, a developer of pharmaceutical products, to provide process development support and manufacture of clinical-stage antibodies.
Subscribe to our email newsletter
The companies have commenced the work at CMC Biologics’ Bothell manufacturing facility.
Daiichi Sankyo Biopharmaceutical Technology Research Laboratories vice president Junichi Koga said CMC Biologics is known for its experience and excellent quality.
"Together we have created a responsive working relationship to bring best-in-class biologics to patients in need," Koga added.
The financial terms of the deal have not been disclosed.